Combination cancer immunotherapies tailored to the tumour microenvironment.

PubWeight™: 1.54‹?› | Rank: Top 4%

🔗 View Article (PMID 26598942)

Published in Nat Rev Clin Oncol on November 24, 2015


Mark J Smyth1, Shin Foong Ngiow1, Antoni Ribas2, Michele W L Teng3

Author Affiliations

1: Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia.
2: Department of Medicine, Division of Haematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California 90095, USA.
3: Cancer Immunoregulation and Immunotherapy Laboratory QIMR Berghofer Medical Research Institute, Herston, 4006 Queensland, Australia.

Associated clinical trials:

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | NCT00324155

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143) | NCT02017717

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) | NCT01239134

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | NCT01303705

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma | NCT02253992

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | NCT01775631

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | NCT01346358

A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469) | NCT02205333

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | NCT02179918

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | NCT01783938

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | NCT02224781

Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) | NCT02210117

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma | NCT01920191

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | NCT00096278

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | NCT01792050

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) | NCT02178722

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | NCT02302807

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | NCT02216409

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | NCT02452424

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With MEDI4736 and MEDI0680 Monotherapy in Subjects With Select Advanced Malignancies | NCT02118337

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | NCT01316822

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer | NCT00992186

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | NCT00019682

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC) | NCT02453282

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | NCT02331875

TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | NCT02254772

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | NCT02381314

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | NCT02358031

Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | NCT00389285

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | NCT02471846

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | NCT02369874

AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer | NCT02298946

Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM | NCT00648739

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | NCT02444793

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (IMPALA) | NCT02077868

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | NCT02395172

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma | NCT00349934

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (LIFT) | NCT01275209

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003) | NCT02526017

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes | NCT01496495

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab | NCT02384954

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (KIRMONO) | NCT01222286


A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | NCT02413827

An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia | NCT02399917

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer | NCT00031278

A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers | NCT02452268


A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence | NCT00129519

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | NCT00655837

Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission | NCT02530125


Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | NCT01826864

Articles citing this

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature (2017) 1.46

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39

Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol (2016) 0.83

Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res (2016) 0.81

Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med (2016) 0.80

Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80

Molecular and genetic inflammation networks in major human diseases. Mol Biosyst (2016) 0.79

A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med (2017) 0.79

MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res (2016) 0.78

Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med (2017) 0.77

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A (2016) 0.76

Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials (2016) 0.76

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology (2016) 0.76

Microfluidic models for adoptive cell-mediated cancer immunotherapies. Drug Discov Today (2016) 0.76

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants. Oxid Med Cell Longev (2017) 0.76

Longitudinal microcomputed tomography-derived biomarkers for lung metastasis detection in a syngeneic mouse model: added value to bioluminescence imaging. Lab Invest (2016) 0.75

Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Front Immunol (2017) 0.75

The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun (2017) 0.75

Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol (2016) 0.75

Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials (2016) 0.75

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight (2017) 0.75

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology (2017) 0.75

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology (2016) 0.75

CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology (2016) 0.75

Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. Clin Cancer Res (2016) 0.75

Worldwide malaria incidence and cancer mortality are inversely associated. Infect Agent Cancer (2017) 0.75

Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. J Immunol Res (2016) 0.75

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. Clin Transl Med (2017) 0.75

Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol (2017) 0.75

Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol (2016) 0.75

Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75

A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. Mol Ther Nucleic Acids (2016) 0.75

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology (2016) 0.75

Macrophage regulation of B cell proliferation. Cell Immunol (2017) 0.75

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Oncotarget (2016) 0.75

Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest (2017) 0.75

Roles for Innate Immunity in Combination Immunotherapies. Cancer Res (2017) 0.75

PD1 functions by inhibiting CD28-mediated co-stimulation. Clin Transl Immunology (2017) 0.75

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer (2017) 0.75

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol (2017) 0.75

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget (2017) 0.75

Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol (2017) 0.75

Articles cited by this

(truncated to the top 100)

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Signatures of mutational processes in human cancer. Nature (2013) 21.63

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01

The future of immune checkpoint therapy. Science (2015) 5.59

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Neoantigens in cancer immunotherapy. Science (2015) 5.16

CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44

Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med (2014) 3.62

Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12

Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76

Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67

Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res (2009) 2.61

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol (2014) 2.59

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity (2014) 2.28

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26

Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell (2014) 2.24

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14

Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol (2001) 2.13

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13

Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10